Antibiotic pharmacodynamics in cerebrospinal fluid

被引:177
作者
Lutsar, I [1 ]
McCracken, GH [1 ]
Friedland, IR [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA
关键词
D O I
10.1086/515003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CSF half-lives of lipophilic agents, such as quinolones, are similar to those in serum and peak concentrations in CSF are achieved relatively quickly. In contrast, the pharmacokinetics of hydrophilic agents (β-lactams and vancomycin) in CSF often differ from those in serum. In particular, the half-lives of these agents in CSF tend to be extended, and the time to achieve peak concentrations in CSF is delayed. Hydrophilic antibiotics, such as β-lactams, penetrate poorly through the BBB, but CSF penetration is significantly increased in the presence of inflammation. In contrast, lipophilic antibiotics, such as quinolones, enter the CSF more efficiently and their penetration is not inflammation dependent. The pharmacodynamic properties of antibiotics in CSF are generally similar to those in other body sites; β-lactam agents and vancomycin are time-dependent, whereas the quinolones and aminoglycosides are concentration-dependent. However, a notable difference from infections in other sites is that quinolones have a short PAE in CSF and need to continually exceed the MBC for maximal effectiveness. Thus, in CSF, quinolines demonstrate features of both concentration-dependency and time-dependency, evidence that the AUC/MBC is an important predictor of effectiveness. With the exception of quinolones, many antibiotics appear to have prolonged sub-MIC effects and longer half-lives in CSF than in serum, suggesting that dosing intervals longer than those used traditionally would be effective in meningitis. However, this requires clinical verification.
引用
收藏
页码:1117 / 1127
页数:11
相关论文
共 105 条
[1]   Transporting therapeutics across the blood-brain barrier [J].
Abbott, NJ ;
Romero, IA .
MOLECULAR MEDICINE TODAY, 1996, 2 (03) :106-113
[2]   A critical evaluation of vancomycin for treatment of bacterial meningitis [J].
Ahmed, A .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (09) :895-903
[3]   Once-daily gentamicin therapy for experimental Escherichia coli meningitis [J].
Ahmed, A ;
Paris, MM ;
Trujillo, M ;
Hickey, SM ;
Wubbel, L ;
Shelton, SL ;
McCracken, GH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (01) :49-53
[4]  
AHMED A, 1996, 34 ANN M INF DIS SOC
[5]  
AMSDEN GW, 1995, MANDELL DOUGLAS BENN, P492
[6]  
ARGUEDASMOHS A, 1997, 37 INT C ANT AG CHEM
[7]  
BARZA M, 1978, SCAND J INFECT DIS, P109
[8]   HYDROCEPHALUS SHUNT INFECTIONS [J].
BAYSTON, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 :75-84
[9]   CSF PRODUCTION IN ACUTE VENTRICULITIS [J].
BREEZE, RE ;
MCCOMB, JG ;
HYMAN, S ;
GILLES, FH .
JOURNAL OF NEUROSURGERY, 1989, 70 (04) :619-622
[10]   INFLUENCE OF DEXAMETHASONE ON EFFICACY OF CEFTRIAXONE AND VANCOMYCIN THERAPY IN EXPERIMENTAL PNEUMOCOCCAL MENINGITIS [J].
CABELLOS, C ;
MARTINEZLACASA, J ;
MARTOS, A ;
TUBAU, F ;
FERNANDEZ, A ;
VILADRICH, PF ;
GUDIOL, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (09) :2158-2160